Ligand Pharmaceuticals Incorporated
LGND
$213.21
-$5.77-2.64%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -13.35M | 44.78M | 117.27M | 4.85M | -42.45M |
| Total Depreciation and Amortization | 8.22M | 8.21M | 9.16M | 8.10M | 8.77M |
| Total Amortization of Deferred Charges | 1.28M | 1.05M | 926.00K | 537.00K | 707.00K |
| Total Other Non-Cash Items | 46.65M | -17.42M | -103.65M | 8.49M | 12.70M |
| Change in Net Operating Assets | 5.89M | 9.29M | -10.62M | -6.17M | -5.17M |
| Cash from Operations | 48.69M | 45.92M | 13.09M | 15.80M | -25.45M |
| Capital Expenditure | -228.00K | -9.00K | -15.00K | -214.00K | -214.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -8.09M | -- | -- | -- |
| Other Investing Activities | -94.12M | -10.01M | -353.43M | -10.45M | 5.11M |
| Cash from Investing | -94.35M | -18.10M | -353.45M | -10.67M | 4.89M |
| Total Debt Issued | -- | 0.00 | 460.00M | -- | -- |
| Total Debt Repaid | -7.00K | -7.00K | -113.26M | -7.00K | -7.00K |
| Issuance of Common Stock | 7.65M | 9.30M | 25.74M | 8.24M | 4.22M |
| Repurchase of Common Stock | -21.73M | -344.00K | -15.22M | -145.00K | -8.89M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -50.00K | -617.00K | 52.38M | 6.91M | -71.00K |
| Cash from Financing | -14.13M | 8.33M | 409.65M | 15.00M | -4.75M |
| Foreign Exchange rate Adjustments | -44.00K | -590.00K | -400.00K | 2.29M | 1.06M |
| Miscellaneous Cash Flow Adjustments | -- | -- | 2.82M | -2.74M | -78.00K |
| Net Change in Cash | -59.83M | 35.55M | 71.71M | 19.68M | -24.32M |